6 Ways to Elevate Your Machine Translation Strategy

Future-proof your MT strategy for clinical and regulatory content with this guide.

AI Driven

With 2025 well underway, innovators in the global life sciences and pharmaceutical industries continue to question how to maximize efficiencies and reduce complexities in clinical and regulatory content development and localization. As part of the broader technological roadmap, AI and automation remain front and center as key players in taking these workflows to new heights. Here are six approaches to ensure you don’t miss a pivotal step when adapting and applying your process.

translation_factory

1. Translation Model Customization

The pharmaceutical industry commands precision and optimal quality in all content. MT models should therefore be tailored and regularly updated such that they align with industry-specific terminology and have built-in glossaries that enforce accuracy and consistency across all translated materials. Using translation memories (TMs) and engine customization with company-specific data enables teams to repurpose pre-approved translations to cut down on review cycle times and ensure content uniformity when compared to “off-the-shelf” machine translation models.

Learn more about how machine translation drives success ›

2. Integration with Clinical & Regulatory Technologies

From a workflow perspective, MT can be integrated directly into additional content repositories, like an eTMF, RIM, web CMS, and more. This generates faster and more secure MT workflows that can be initiated from those same systems where your documents are authored and stored, in a secure “closed loop” ecosystem. In addition, integration with technologies like generative AI and natural language processing can yield more sophisticated language understanding and translation than MT alone. Explore 5 essential use cases for AI automation in regulatory content.

clinical_practice
contact

3. Increased Use of Multimodal Translation

With continually evolving capabilities and new use cases being identified, MT may extend beyond text to include multimodal elements, such as translating audio, images, graphs, and other visual content commonly found in pharmaceutical documents. This could enhance the overall translation of complex information and provide significant efficiencies in areas like patient recruitment and medical information, which more frequently utilize multi-channel and non-document-based content.

4. Enhanced Post-Editing Automation

Automation of post-editing processes has become more sophisticated, mitigating the need for extensive human intervention post-MT. Generative AI tools embedded within the review module leveraged by post-editors results in more streamlined workflows and rapid delivery of high-quality, fully reviewed translations.

post_editing
Forrester TEI GlobalLink for Life Sciences

5. Compliance Monitoring and Reporting

MT systems have evolved to incorporate multifaceted tools, such as built-in compliance monitoring features, ensuring that translations comply with specific regulatory requirements through automated checks for terminology consistency and language compliance, for example.

Key steps for regulatory submissions ›

6. Real-Time Collaboration Tools

The integration of real-time collaboration tools within MT platforms enhances efficiency and enables global teams to work simultaneously on translation projects. Features like live editing, instant feedback, and collaborative workflows help cut down the time needed to make documents submission-ready.

discussion regulatory

Additional Resources & Expert Perspectives

eConsent: Why the Content Matters as Much as the Tech

Blog

Insights from a conversation with Edwin Cohen, Principal Consultant at CM Flow Instrument Creation and Mark P Wade Global Practice Leader & COA SME, TransPerfect Life Sciences For all the attention paid to the systems, platforms, and integrations behind electronic informed consent (eConsent), the real barrier to adoption may not be technical at all. It may be the words on the page. That's the central argument from Edwin Cohen, whose research has examined how ...

eConsent: Why the Content Matters as Much as the Tech
Webinar

LifeSci Talks COA Series | The "Frankenstein Instrument" Problem: Why Some PRO Measures Don't Fit Today's Patients

Are the COA Instruments we've relied on for decades still measuring what matters to patients today? In this episode, Mark Wade sits down with Kathrin Fischer PhD, Patient-Centered Outcome Strategy Lead at Boehringer Ingelheim and ISOQOL Director-at-Large Term: 2024 – 2027, ...
Blog

Has eCOA Lived up to Its Promise? A Retrospective View on the Evolution of Electronic Clinical Outcome Assessments

The Evolution of eCOA: Progress, Challenges, and the Road AheadElectronic clinical outcome assessments (eCOAs) were expected to make paper obsolete by improving data quality, reducing missing data, and enabling decentralized clinical trials.More than two decades later, that...
Success Stories

How a Leading eCOA Provider Cut Timelines by 60% with GlobalLink Strings Integration

Discover how a leading eCOA provider slashed project timelines by 30% and screenshot review cycles by more than 60% by integrating GlobalLink Strings into its platform. This case study breaks down the roadmap, the rollout, and the efficiency gains that followed. See how ...
Blog

Breaking Down Silos: The Key to Effective Collaboration and Safety Signal Management

Insights from an XTalks webinar on collaboration between Medical Information, Pharmacovigilance, and Regulatory AffairsIn pharmaceutical organizations, critical safety information is often received by multiple teams. Medical Information (MI) receives inquiries from healthcare...
Checklist

The 5-Step AI Readiness Checklist for Medical Device Manufacturers

Only one in four manufacturers using process AI say it's meeting expectations. The gap between those results and the rest comes down to preparation. This checklist is built from patterns shared by manufacturers that are seeing results, along with the gaps most commonly found ...
Webinar

LifeSci Talks COA Series | eConsent: Why the Content Matters as Much as the Tech

In this episode of LifeSci Talks, Mark Wade, Global Practice Leader at TransPerfect Life Sciences, sits down with Edwin Cohen, Principal Consultant at C&Flow, to talk about eConsent adoption in clinical trials. They discuss the research behind why animated, electronic consent ...

Reach out to our team of AI and MT experts to get started today.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.